Relmada Therapeutics (RLMD) Tops Q2 EPS by 6c

Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.84), $0.06 better than the analyst estimate of ($0.90).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Aspire Biopharma to acquire automotive supplier for $30 million
• Independent Bank receives regulatory approval for HCB Financial acquisition